期刊文献+

心脏起搏患者血浆利钠肽水平与生理活动量的关系

Daily physical activity and plasma natriuretic peptides level in patients with implanting pacemaker
下载PDF
导出
摘要 目的了解心脏起搏术后患者生理活动量与血浆心房利钠肽(ANP)、脑钠肽(BNP)水平的相关性及不同等级生理活动量之间血浆ANP、BNP水平的差异。方法用放射免疫法测定62例起搏患者的血浆ANP、BNP浓度,其中DDD17例,VVI39例,VVIR2例,VDD4例,根据特定活动量等级问卷调查来判断起搏患者的生理活动量,选择Ⅰ级、Ⅱ级及Ⅲ级入组进行研究。结果起搏患者生理活动量与血浆ANP水平有良好的相关性(r=0.39,P<0.01),生理活动量与血浆BNP水平相关性更显著(r=0.63,P<0.01)。血浆ANP水平在生理活动量Ⅲ级>Ⅱ级(P<0.05),>Ⅰ级(P<0.01),血浆BNP水平在生理活动量Ⅲ级>Ⅱ级(P<0.001),>Ⅰ级(P<0.001)。结论起搏患者的生理活动量与血浆ANP、BNP水平显著相关,可以用血浆ANP、BNP水平大致判断起搏患者的生理活动量,间接判断患者的心功能。且以血浆BNP水平衡量患者的生理活动量较血浆ANP水平更敏感。 Objectives To determine whether daily physical activity scales after pacemaker implantation is correlated with plasma ANP and /or BNP.Methods The plasma ANP and BNP levels were measured by radioimmunoassay in 62 patients with pacemaker implantation DDD17, VVI39, VVIR2, VDD4. Daily physical activity scales were evaluated by a specific activity scale questionnaire. Results There were significant correlation bet ween daily physical activity scales and plasma BNP (r=0.63, P<0.001) and ANP (r=0.39, P<0.01) levels, plasma ANP level in patients with daily ph ysical activity classⅢ was significantly higher than that in classⅡ(P<0.0 5) and classⅠ(P<0.01); while plasma BNP level in classⅢ significantly, higher than in classⅡ(P<0.001) and classⅠ(P<0.0001). Conclusions Plasma ANP or BNP levels can determine daily physical activity; the higher the level of daily physical activity scale, the lower the plasma ANP or BNP levels. BNP level is more sensitive than ANP level.
出处 《安徽医科大学学报》 CAS 北大核心 2005年第3期252-254,共3页 Acta Universitatis Medicinalis Anhui
基金 安徽省重点科研项目(编号:03023047)
关键词 心脏起搏 人工 心钠素 cardiocal pacing,avtificial atrial natriuretic factor brain natriuretic peptide physical activity
  • 相关文献

参考文献8

  • 1Kuster GM, Tanner H, Printzen G et al. B-type natriuretic peptide for diagnosis and treatment of congestive heart failure. Swiss Med Wkly, 2002;132(43-44):623~8.
  • 2Clerico A, Iervasi G, Del Chicca MG et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest,1998;21(3):170~9.
  • 3Wieczorek SJ, Hager D, Barry MB et al. Correlation of B-type natriuretic peptide level to 6-min walk test performance in patients with left ventricular systolic dysfunction. Clin Chim Acta,2003;328(1-2):87~90.
  • 4Sasaki T, Kubo T, Komamura K et al. Effects of long-term treatment with pimobendan on neurohumoral factors in patients in patients with non-ischemic chronic moderate heart failure. J Cardiol, 1999;33(4):317~25.
  • 5Horie H, Tsutamoto T, Ishimoto N et al. Plasma brain natriuretic peptide as a biochemical marker for atrioventricular sequence in patients with pacemakers. Pacing Clin Electrophysiol,1999;22(2):282~90.
  • 6Mitani H, Hashimoto H, Isshiki T et al. Heaith-related quality of life of Japanese patients with chronic heart failure: assessment using the Medical Outcome Study Short Form 36. Cir J, 2003;67(3):215~20.
  • 7Gosker HR, Lencer NH, Franssen FM et al. Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. Chest, 2003;123(5):1416~24.
  • 8Maisel AS, Koon J, krishnaswamy P et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiograph to determine left ventricular dysfunction. Am Heart J, 2001;141(3):367~74.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部